邵幼雲 醫師

臺大醫院腫瘤醫學部

Combining Antiangiogenic Therapy with Immune Checkpoint Inhibitor for Advanced Hepatocellular Carcinoma

Take home messages
1. IMbrave150 confirms the benefits of combining antiangiogenic therapy with immunecheckpoint inhibitors as advanced HCC treatment
2. Bevacizumab+ atezolizumab is the first regimen that beats sorafenib in overall survival benefits for advanced HCC patients
3. Other antiangiogenic therapy + immune checkpoint inhibitor combinations have encouraging phase 1 study results but need to be confirmed in phase 3 studies

相關資訊

提升醫療品質

Promoted to the medical quality

台灣肝癌醫學會 (TLCA)
Leave a comment

各位會員您好,如果您針對活動內容有任何想法,歡迎留下您的回饋與建議,我們將依據您們的回饋來調整接下來幾集的影片內容,謝謝您對學會的支持與指教。

留言功能僅在新影片上傳後三天內開啟。

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.